John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.

As obesity clinical trials evolve, there is a growing emphasis on how decentralisation and new technologies can play a role.

Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related ...

So far, Zepbound has seemed superior, as testing showed treatment helped people with obesity lose up to 21% of their body weight. The comparative figure for Wegovy was 16% in the Phase 3 trials Novo ...

Popular weight-loss medications including Ozempic and Wegovy contain a drug that seems to decrease cravings for food and ...

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...

Semaglutide vs liraglutide treatment demonstrated superior weight loss at 1 year and 10% weight loss achievement among patients with obesity.

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...